Cognitive function enhancement

Cognitive function enhancement is not a specific molecular target (such as a receptor, enzyme, or transporter), but rather a clinical outcome or therapeutic objective involving the improvement of mental processes like memory, attention, and executive function. This physiological process is a primary goal in treating neurodegenerative conditions like Alzheimer's disease and neuropsychiatric disorders like ADHD or schizophrenia [NIH/NIA, 2021; StatPearls, 2023]. Pharmacologically, this effect is achieved by modulating distinct molecular targets, including acetylcholinesterase (AChE) to increase acetylcholine levels, N-methyl-D-aspartate (NMDA) receptors to regulate glutamate signaling, and monoamine transporters to enhance dopamine and norepinephrine availability [PubMed: 22841014]. Because the term describes a complex set of biological and psychological improvements rather than a single binding site for a drug, it is classified as a physiological effect or therapeutic indication rather than a molecular target in drug discovery.

Other names

Nootropic effectCognitive enhancementMemory enhancementCognitive restorationNeuroenhancement

Not applicable; this is a clinical effect mediated by various mechanisms including acetylcholinesterase inhibition, NMDA receptor antagonism, and catecholamine reuptake inhibition [StatPearls: Nootropics].